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Abstract There is significant heterogeneity in the clini-
copathological characteristics of intermediate hepatocellu-
lar carcinoma (IHCC). This also translates to treatment as
transarterial chemoembolization (TACE) is used as first-
line therapy for patients with IHCC; however, in Asia liver
resection (LR) is preferred. Prognostic tools are required to
help guide clinicians in deciding treatment options. This
study evaluates the prognostic impact of the Intermediate
Stage Score (ISS) on overall survival (OS) in a large,
multicenter cohort study of patients with IHCC treated with
TACE or surgery LR. Consecutive patients from centers in
Japan, Korea, Italy and the United Kingdom who under-
went TACE or LR between 2001 and 2015 were enrolled.
Propensity score (PS) adjustment was used to remove
residual confounding and applied to LR (n = 162) and
TACE (n = 449) to determine the prognostic significance
of ISS. Among 611 patients, 75 % were men and 25 %
women, with a mean age of 70 years. ISS is a valid
prognostic tool in the BCLC-B population with a median
OS ISS 1–51, 2–38.3, 3–24.3, 4–15.6, 5–16 months
(p\ 0.0001). ISS was analyzed within each treatment
modality, and this was a valid prognostic score among
those treated with TACE and LR (p\ 0.001 vs.
p = 0.008). In the PS-adjusted model, ISS retained its
prognostic utility in TACE and LR groups (p\ 0.001 vs.
p = 0.007). ISS optimizes prognostic prediction in IHCC,
reducing clinical heterogeneity, and is a useful tool for
patients treated for TACE or LR.
Keywords Hepatocellular cancer  Transarterial
chemoembolization  Liver resection  Prognosis 
Multicenter
Introduction
Hepatocellular carcinoma (HCC) is one of the leading causes
of cancer-related death in patients with liver cirrhosis, with
more than new 700,000 cases diagnosed yearly worldwide
[1, 2]. Over the past few decades, it has become clear that the
natural history of HCC strongly depends on anatomical
stage, underlying liver function and overall patients’ physi-
cal status: this has led to the development of several prog-
nostic algorithms with intent to optimize treatment [3–7].
The Barcelona Clinic Liver Cancer (BCLC) stage
includes prognostic variables such as tumor stage, perfor-
mance status, and Child–Turcotte–Pugh (CTP) class [8].
Prospective validation of the BCLC staging system has
demonstrated reliable prognostic subdivision of HCC
[9, 10]. Due to its association with treatment allocation, the
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BCLC algorithm has received formal endorsement by
organizations such the European Association for the Study
of the Liver (EASL) and the American Association for the
Study of Liver Diseases (AASLD) [11–13]. However, there
is marked heterogeneity in the reported 3-year survival in
BCLC-B stage disease of 10–40 %. Therefore, formulating
appropriate treatment strategies for the individual patient is
difficult within this nebulous BCLC-B staging system.
According to the BCLC staging system, transarterial
chemoembolization (TACE) is recommended as first-line
treatment for patients with IHCC or BCLC-B. Two ran-
domized controlled trials have shown an approximate 50 %
reduction in mortality in patients treated with TACE
compared to controls [14, 15]. A significant OS benefit
from TACE has been further consolidated by two separate
meta-analyses [16], which however re-defined the magni-
tude of benefit of TACE due to patient and procedural
heterogeneity, resulting in some of the pooled studies not
meeting their primary survival endpoints [17].
Issues such as the relative efficacy of TACE and the risk
of adverse events among this group of patients results in
the use of sorafenib, trial therapies or best supportive care
[18, 19]. Alternatively, clinicians who do not adhere to
BCLC guidelines offer other treatments such as resection
or transarterial radioembolization (TARE) if IHCC patients
meet local criteria [20, 21]. Therefore, despite the presence
of consensus guidelines, there is variation in treatment in
patients with BCLC-B disease. There is an urgent need for
improved prognostication and subsequent stratification of
management for patients with IHCC.
Bolondi et al. [22] created a prognostic score to further
subdivide patients with IHCC in an effort to improve
treatment allocation among this complex group. The
Intermediate Stage Score (ISS) consists of five stages and
includes CTP classification, ECOG performance status,
portal vein thrombus and specific size criteria (Table 1).
On the basis of the score, the authors recommended that
patients can be offered first-line options such as TACE
while patients with advanced stage (Quasi-C) should
receive sorafenib [22]. There have been mixed outcomes in
demonstrating the efficacy of this score. Two studies have
demonstrated an association between ISS and OS among
patients treated with bland transarterial embolization
(TAE) and TACE (N = 580, 466) [23, 24]. However, in a
separate European study, the score did not achieve prog-
nostic significance (N = 254) [25]. Our intent was to val-
idate the prognostic ability of the ISS in patients with
intermediate-stage HCC (BCLC-B) by using propensity
score analysis in diverse Eastern and Western populations
treated with either surgical resection (LR) or TACE.
Materials and methods
Patient population
All centers in this study were involved in prospective col-
lection of data from patients with a diagnosis of HCC made
according to radiological or histological criteria, between
2001 and 2015. Patients were recruited from Hammersmith
Hospital, London, St Mary’s Hospital, Seoul, University of
Novara, and, Dokkyo Medical University, Dokkyo and
Kinki University, Osaka). Informed consent was obtained
from all patients recruited in this study in accordance with
the Declaration of Helsinki and Good Clinical Practice
(GCP) guidelines. Ethical approval for this study was
obtained from the East London Research Ethics Committee.
Clinical variables were retrieved include patient demo-
graphics, complete blood count, albumin, aspartate and
alanine aminotransferases (AST, ALT), alkaline phos-
phatase (ALP) alpha-fetoprotein (AFP), the international
normalized ratio (INR) value and underlying etiology of
liver diseasewas also identified. Patients with IHCC (BCLC-
B) were categorized into five groups as per the criteria
described by Bolondi et al. [22] (Table 1). Liver functional
reserve was estimated using the CTP classification.
Table 1 BCLC-B sub-classification by Bolondi et al
BCLC sub-stage (ISS) B1 (1) B2 (2) B3 (3) B4 (4) Quasi-C (5)
Child–Pugh score 5–6–7 5–6 7 8–9 5–6
Beyond milan and within
Ut-7
In Out Out Any Any
ECOG PS 0 0 0 0–1 0
Portal vein thrombosis No No No No Yes
1st line treatment TACE TACE or TARE Best Supportive Care Sorafenib
Alternative LT TACE ? Ablation Sorafenib Research trials TACE
Sorafenib
LT TACE or TARE
Proposed sub-classification and management recommendations for intermediate hepatocellular carcinoma as detailed by Bolondi et al. [15]
BCLC barcelona liver clinic, ECOG Eastern Cooperative Oncology Group, PS performance status, LT liver transplantation, TACE transarterial
chemoembolization, TARE transarterial radioembolization
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Tumor staging was described as the number of focal
hepatic lesions and maximum diameter detected during
contrast enhancement phase on computerized tomography.
The Milan criteria and up-to-seven criteria (Up-to-7) were
used to categorize size for calculating the ISS. The Milan
criteria is defined as a single lesion \5 cm, up to three
lesions\3 cm, the absence of gross vascular invasion or
nodal or distant metastases [26]. Within the Up-to-7 cri-
teria, seven is the sum of the size (centimeters) and the
number of tumors for any given HCC [27].
Statistical analysis
Continuous variables were presented as a median and
range, and associations were tested using Mann–Whitney
U or Student’s t test as appropriate. Categorical variables
with absolute or relative frequencies were tabulated and or
Fisher’s exact test, where appropriate. The OS rates for
various ISS levels in all patients were analyzed using
Kaplan–Meier method, and log-rank test was used to
compare survival time. Univariate analyses of prognostic
variables were completed with the Cox proportional haz-
ards model. All statistical analyses were completed using
two-sided test, and statistical significance was achieved
where p\ 0.05.
The date of HCC diagnosis till the date of death, loss to
follow-up or study censoring (1st January 2016) was used
to calculate overall survival. All patients were monitored
with routine follow-up till the dates of death, loss to fol-
low-up or study censoring.
Propensity score adjustment (PS) is a statistical method
to reduce the effect of residual confounding in two groups
Table 2 Patient demographic at initial HCC diagnosis
Baseline characteristic All patients (%), median,
range N = 611
TACE intervention (%), median,
range N = 449
LR intervention (%), median,
range N = 162
p value
Age, years 70 (28–89) 72 (33–89) 68 (28–84) \0.0001
Gender 0.39
Male 460 (75.3) 334 (74.4) 126 (77.8)
Female 151 (24.7) 115 (25.6) 36 (22.2)
Aetiology
Hepatitis B infection 102 (16.7) 64 (14.3) 38 (23.4) 0.01
Hepatitis C infection 369 (60.4) 268 (59.7) 101 (62.3) 0.36
Alcohol related 97 (15.9) 97 (21.6) – –
Child–Turcotte–Pugh class 0.0003
A5 274 (44.8) 221 (49.2) 53 (32.7)
A6 201 (32.9) 128 (28.5) 73 (45.0)
B7 101 (16.5) 69 (15.4) 32 (19.8)
B8 27 (4.4) 23 (5.1) 4 (2.5)
B9 7 (1.2) 7 (1.5) –
Maximum tumor diameter \0.0001
\7 cm 509 (83.3) 403 (89.8) 106 (65.4)
C7 cm 102 (16.7) 46 (10.2) 56 (34.6)
Portal vein thrombus –
Present 5 (1.1) 5 (1.1) –
Absent 444 (98.9) 444 (98.9) –
AFP, ng/mL 33 (1–[ 1000) 32 (1–[ 1000) 43.5 (1–[ 1000) 0.44
Platelet count, 9109/L 128 (26–470) 123 (26–453) 146 (44–470) 0.0008
ISS \0.0001
1 104 (17.0) 42 (9.4) 62 (38.3)
2 384 (62.8) 309 (68.8) 75 (46.3)
3 84 (13.8) 63 (14.0) 21 (13.0)
4 34 (5.6) 30 (6.7) 4 (2.5)
5 5 (0.8) 5 (1.1) –
Median OS in months (95 % CI) 37 (33, 39.3) 34.8 (29.6, 38.9) 40 (34,47) 0.09
AFP alpha-fetoprotein, INR international normalized ratio, BScore scoring system for intermediate HCC, OS overall survival, TACE transarterial
chemoembolization, LR liver resection
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[28]. In this study, PS was used to reduce the effect of
residual confounding in the cohort by adjusting for con-
founding variables that are not accounted for within ISS
classification, such as age, gender, hepatitis status and INR
that impact treatment options. Cox regression analysis was
used to determine the effect of ISS adjusted for PS quartiles
in TACE and LR treatment groups. An interaction test was
performed to determine the statistical significance of ISS in
TACE and LR groups. Statistical analyses were performed
using R version 3.1.2 (ww.r-project.org) and SAS 9.4 (SAS
Institute Inc. Cary, North Carolina).
Results
Patient characteristics
Our study population consisted of 611 BCLC-B patients
diagnosed with HCC across five centers (Table 2). The
majority of patients underwent TACE (73.4 %) as first
anticancer treatment, while 27.6 % were offered liver
resection. Patients undergoing liver resection were younger
(p\ 0.001), while a higher proportion of patients under-
going TACE were Hepatitis B positive (p = 0.01). Five
patients treated with TACE had portal vein thrombosis
(PVT) and were classified as ‘Quasi C’ or ISS 5. There was
a significant difference in the CTP classification between
LR and TACE, with a higher proportion of patients with
CTP[A6 receiving TACE (p\ 0.01). The median OS
(OS) of the overall population was 37 months (95 % con-
fidence interval (CI) 33.0–39.3 months). The 1- and 3-year
survival rates were 84.1, and 21.9 %, respectively. There
was no significant difference between the median OS
between TACE and LR subgroups (34.8 vs. 40 months,
p = 0.09).
ISS characteristics and OS
In univariate analyses of the cohort, male gender, positive
hepatitis B status and INR were variables that were sig-
nificant for increased mortality and were not within the ISS
prognostic score (Table 3). There was a difference in the
ISS categories between TACE and LR groups, with a
higher proportion of patients with ISS 2 or greater treated
with TACE and those with an ISS of 2 or less treated with
LR (p\ 0.0001). There were no significant differences in
baseline characteristics between ISS groups (Table 4). Due
to the small number of patients with ISS 4 and 5, these
were analyzed together to improve statistical validity.
Significant differences in OS were observed between the
Table 3 Univariate analysis of factors that predict overall survival in patients with intermediate hepatocellular carcinoma (IHCC) treated with
TACE or LR
Baseline characteristic Hazard ratio (HR) 95 % confidence interval (CI) p value
Age, years 1.01 0.99–1.01 0.32
Gender (F vs. M) 1.40 1.11–1.77 0.005
Aetiology
Hepatitis B infection 0.69 0.51–0.93 0.01
Hepatitis C infection 1.23 0.99–1.53 0.06
Child–Turcotte–Pugh class
A5
A6 1.24 0.98–1.57 0.08
B7 1.62 1.20–2.19 0.002
B8 2.56 1.58–4.13 0.00
B9 3.22 1.19–8.72 0.02
Maximum tumor diameter (\7 vs. C7 cm) 1.11 0.86–1.43 0.42
Portal Vein Thrombus 1.51 0.48–4.71 0.48
AFP, ng/mL 1.00 0.99–1.00 0.07
Platelet Count, 9109/L 0.99 0.996–0.999 0.03
ISS
1 – –
2 1.39 1.03–1.87 0.03
3 2.29 1.55–3.39 0.00
4 3.19 1.95–5.23 0.00
5 2.27 0.71–7.29 0.17
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different ISS groups ranging from 51 (ISS 1) to 16 months
(ISS 4 and 5; p\ 0.001), (Table 3; Fig. 1).
ISS retains prognostic utility in propensity score
adjustment analysis
When considering the prognostic utility of the ISS
according to treatment received, ISS was significant in
TACE (p = 0.0003) and LR (p = 0.008). ISS retained its
prognostic ability following PS adjustment. In the PS-
adjusted model, among patients undergoing LR, ISS of 4
and 5 implied poor prognosis compared to ISS 1 [hazard
ratio (HR) 2.13 (95 % CI 0.64, 7.02)], such that ISS was a
prognostic score among patients treated with LR [Likeli-
hood ratio test (LRT) p = 0.007]. This comparison
between ISS 4 and 5 to ISS 1 was evident for patients
treated with TACE [HR 3.59 (95 % CI 2.07, 7.57)], (LRT
p\ 0.001, Table 5). On assessing the prognostic value of
ISS on either treatment, there was no evidence of a dif-
ference in ISS subgroups between LR and TACE groups
(p = 0.23).
Discussion
This is the first large, multi-center study to validate the
prognostic ability of the ISS in patients with BCLC-B stage
disease, independent of treatment received. Bolondi and
colleagues divided BCLC-B stage disease into sub-classi-
fications based on trial results and expert opinion in an
effort to reduce heterogeneity in survival in this otherwise
disparate patient group. While their method has been val-
idated in a number of papers, this the largest study incor-
porating both Eastern and Western populations that adheres
to the BCLC-B classification. As such this is the first study
to explore the use of LR within the BCLC-B classification,
albeit in small numbers. PS has been used to reduce
Table 4 Sub-classification of BCLC-B with intermediate stage score (ISS) and corresponding characteristics
Factors Total ISS 1
(n = 104)
ISS 2
(n = 384)
ISS 3
(n = 84)
ISS 4
(n = 34)
ISS 5
(n = 5)
p value
Age, median years 70 67.4 69.7 68.9 66.1 65.8 0.07
Gender 0.088
Male 460 (75.3) 77 (74.0) 294 (76.6) 61 (72.6) 24 (70.6) 4 (80.0)
Female 151 (24.7) 27 (25.9) 90 (23.4) 23 (27.3) 10 (29.4) 1 (20.0)
Aetiology
Hepatitis B infection 102 (16.7) 26 (25.0) 61 (15.9) 10 (11.9) 5 (14.7) – 0.33
Hepatitis C infection 369 (60.4) 60 (57.7) 242 (63.0) 43 (51.2) 20 (58.8) 4 (80.0) 0.54
Alcohol related 97 (15.9) 11 (10.6) 57 (14.8) 19 (22.6) 9 (26.5) 1 (20.0) 0.34
Alpha-fetoprotein 33 (1–[ 1000) 2279.4 5903.6 3923.2 1262.9 4525.5 0.96
Child–Turcotte–Pugh class \0.0001
A5 274 (44.8) 53 (50.9) 219 (57.0) – – 2 (40.0)
A6 201 (32.9) 35 (33.7) 164 (42.7) – – 1 (20.0)
B7 101 (16.5) 16 (15.4) – 84 (100) – 2 (40.0)
B8 27 (4.4) – – – 27 (100) –
B9 7 (1.2) – – – 7 (100) –
Maximum tumor diameter 0.0004
\7 cm 509 (83.3) 104 (100) 309 (80.5) 65 (77.4) 28 (82.4) 3 (60.0)
C7 cm 102 (16.7) – 75 (19.5) 19 (22.6) 6 (17.6) 1 (20.0)
Median overall survival in
months
37 51 38.3 24.3 15.6 16 \0.0001
Fig. 1 Cumulative mortality stratified by intermediate stage score
(ISS) for all patients with intermediate hepatocellular carcinoma
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confounders between LR and TACE groups, adding to the
robust nature of the results obtained.
A plethora of prognostic scores have recently been
introduced aiming to improve treatment selection in
patients with BCLC-B stage disease [29–31]. These scores
such as the Hepatoma Arterial Embolization Prognostic
score (HAP score) and Selection for Transarterial
chemoembolization Treatment (STATE) score have
derived prognostic variables within a cohort and subse-
quently validated the scores within an external population
[30, 31]. The recently proposed ART and HAP scores have
attracted significant attention recently particularly as
prognostic markers in patients receiving TACE. The HAP
score consists of two measures of tumor burden (AFP and
size of largest tumor) and two measures of liver function
(albumin and bilirubin) [30]. However, the original study
included patients with BCLC-A, B and C disease, as well
as concerns regarding the independent prognostic ability of
bilirubin, may impact on the overall utility of this score.
The ART score while useful in determining retreatment
with TACE does not contribute to prognostic sub-classifi-
cation within BCLC-B. Recently Ogasawara and col-
leagues derived the CHIP score as a means to delineate
survival heterogeneity in BCLC-B stage tumors [32].
However, in their paper when compared to the ISS, their
novel score showed no real difference in prognostic ability.
The variables included in the ISS are similar to previ-
ously identified scores including markers of liver function
such albumin, bilirubin, and tumor burden. The main dif-
ference with the ISS is that it incorporates three measures
of tumor burden; up-to-7 criteria, size of the largest tumor
and number of tumors. We report considerable variation in
OS from 15.6 to 51 months in our population suggesting
that the variables used by Bolondi et al. are useful in
delineating prognosis further within this patient group.
A key strength of this study is that we used patient
datasets derived from different academic institutions in
both Europe and Asia. While TACE is the recommended
treatment for BCLC-B patients according to American and
European guidelines, in Asian centers, it is not uncommon
to propose surgical management [33, 34]. We have shown
that ISS retains its prognostic ability in LR or TACE in
BCLC-B stage disease prior to and following PS-adjusted
analysis. Resection of liver lesions beyond the Milan cri-
teria in BCLC-B population has been shown to improve OS
compared to TACE treatment [35], and though beyond the
remit of this study, these results suggest that surgical
intervention may be a useful treatment modality in a
carefully selected population group, and does warrant
further investigation in a larger population group within a
prospective study design. ISS appears a useful prognostic
tool within each treatment category, and there is no evi-
dence of a difference in the effects of ISS subgroups
between treatment groups.
However, the inclusion of ‘Quasi C sub-classification’
(ISS 5) and patients with portal vein thrombosis involves a
subgroup recognized to possess a poorer prognosis with
variable treatment options [36]. While we have demon-
strated the prognostic accuracy of the ISS, we have not
validated the treatment allocation aspect of the score as
proposed by Bolondi et al., an aspect that has not been cor-
roborated in any study. In this context, reflection is required
on the use of liver transplant for patients with BCLC-B
disease given the poorer overall prognosis of this patient
group comparedwith BCLC-A in the context of global organ
shortages.We suggest, therefore, that the role of the ISS is in
prognostication rather than as treatment allocation per se.
This is a significant time for the management of HCC as
new therapies emerge on the horizon. Useful prognostic
tools that improve patient selection are crucial in order to
ensure that safe, appropriate and effective therapies are
administered in a timely manner. It is evident from this
large multi-centered study that the ISS offers a useful tool
for clinicians to stratify treatment options, such as TACE
and LR, in the BCLC-B population.
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Table 5 Propensity score-adjusted Cox proportional hazards model of ISS on overall survival within TACE and LR population and overall
likelihood ratio test (LRT), and interaction test to determine effect of ISS between treatments
TACE intervention, hazard ratio (95 % CI) LR intervention median OS in months (95 % CI)? p valuea
ISS 1 – p\ 0.001 – p = 0.007 0.226
ISS 2 1.30 (0.79–2.14) 1.66 (1.06–2.59)
ISS 3 1.97 (1.08–3.58) 2.98 (1.61–5.51)
ISS 4 ? 5 3.95 (2.07–7.57) 2.13 (0.64–7.02)
a Log likelihood ratio test of interaction
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